Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-650 dose escalation in Crohn's disease
NCT00805766Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Dec 2008
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Crohn's Disease Activity Index Change at 8 weeks. Started Dec 2008; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00805766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00805766.